Plasma levels of guanylins are reduced in patients with Crohn’s disease

Abstract

Background: Guanylin (GN) and uroguanylin (UGN) are endogenous ligands for the intestinal receptor guanylate cyclase C (GC-C), an important regulator of intestinal fluid homeostasis. Gene expression and protein levels of GN are suppressed in inflamed intestinal tissue from patients with inflammatory bowel disease (IBD), but knowledge about plasma levels of guanylins in these conditions is sparse. We aimed to investigate the fasting plasma levels of the prohormones proGN and proUGN in patients with Crohn’s Disease (CD) and relate these to levels found in persons with other diarrheal conditions, as well as persons with normal bowel habits.

Methods: Plasma from patients with CD, patients with Familial GUCY2C Diarrheal Disease (FGDS), diarrhea-predominant irritable bowel syndrome (IBS-D) and healthy controls (HC) was analyzed using ELISA assays.

Results: Significantly lower fasting plasma levels of proguanylins were found in CD and FGDS patients, compared to HC. In CD patients, plasma proGN levels correlated negatively with Harvey Bradshaw Index and with number of stools/24 h.

Conclusion: Our data indicate that diarrhea may be a determinant for levels of proGN in plasma, and should be further explored in studies of different diarrheal disorders.

Keywords:

• Crohn’s
• diarrhea
• prouroguanylin
• proguanylin
• FGDS
• IBS
• GUCY2C

Disclosure statement

Odd Helge Gilja has received speaker honoraria from the following companies: AbbVie, Bracco, Almirall, GE Healthcare, Takeda AS, Meda AS, Ferring AS and Allergan; and he has acted as consultant for Bracco, GE Healthcare, and Samsung. Kim Nylund has served as speaker Takeda, MSD, MEDA AS, Ferring Pharmaceuticals. The other authors declare that they have no competing interests.